3.82
price up icon5.52%   0.20
after-market After Hours: 3.82
loading
Pasithea Therapeutics Corp stock is traded at $3.82, with a volume of 134.89K. It is up +5.52% in the last 24 hours and down -28.46% over the past month. Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.
See More
Previous Close:
$3.62
Open:
$3.57
24h Volume:
134.89K
Relative Volume:
0.15
Market Cap:
$3.76M
Revenue:
-
Net Income/Loss:
$-16.28M
P/E Ratio:
-5.8769
EPS:
-0.65
Net Cash Flow:
$-13.75M
1W Performance:
-2.55%
1M Performance:
-28.46%
6M Performance:
-44.80%
1Y Performance:
-46.94%
1-Day Range:
Value
$3.57
$4.35
1-Week Range:
Value
$3.41
$4.35
52-Week Range:
Value
$3.40
$17.40

Pasithea Therapeutics Corp Stock (KTTA) Company Profile

Name
Name
Pasithea Therapeutics Corp
Name
Phone
(818) 422-6172
Name
Address
2110 NARCISSUS CT, VENICE
Name
Employee
8
Name
Twitter
Name
Next Earnings Date
2024-08-11
Name
Latest SEC Filings
Name
KTTA's Discussions on Twitter

Pasithea Therapeutics Corp Stock (KTTA) Latest News

pulisher
Oct 26, 2024

KTTA stock touches 52-week low at $3.6 amid market challenges - Investing.com Australia

Oct 26, 2024
pulisher
Oct 25, 2024

KTTA stock touches 52-week low at $3.6 amid market challenges By Investing.com - Investing.com South Africa

Oct 25, 2024
pulisher
Oct 20, 2024

pasithea therapeutics corp Earnings dates - RTTNews

Oct 20, 2024
pulisher
Oct 07, 2024

(KTTA) Investment Analysis - Stock Traders Daily

Oct 07, 2024
pulisher
Oct 02, 2024

Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Act - GuruFocus.com

Oct 02, 2024
pulisher
Sep 30, 2024

Was there any good news for Pasithea Therapeutics Corp (KTTA) stock in the last session? - US Post News

Sep 30, 2024
pulisher
Sep 27, 2024

Allogene Therapeutics (ALLO) Stock Jumps by 5.15% - GuruFocus.com

Sep 27, 2024
pulisher
Sep 27, 2024

Market cap of Pasithea Therapeutics Corp [KTTA] reaches 6.08M – now what? - The DBT News

Sep 27, 2024
pulisher
Sep 27, 2024

PAS-004 Has Tolerable Safety Profile and Preliminary Efficacy in MAPK-Driven Solid Tumors - OncLive

Sep 27, 2024
pulisher
Sep 27, 2024

Pasithea Therapeutics Corp. (NASDAQ:KTTA) Stock Gains After Private Placement - DRP Journal

Sep 27, 2024
pulisher
Sep 27, 2024

Pasithea Therapeutics drops 19% on $5M private placement - MSN

Sep 27, 2024
pulisher
Sep 27, 2024

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - Marketscreener.com

Sep 27, 2024
pulisher
Sep 27, 2024

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - The Manila Times

Sep 27, 2024
pulisher
Sep 26, 2024

Grid Battery Metals Inc. (TSXV:CELL) (OTCQB:EVKRF) Stock Gains Momentum: Is It Sustainable? - DRP Journal

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics prices $5M at-the-market private placement at $4.10/share - TipRanks

Sep 26, 2024
pulisher
Sep 26, 2024

Technical Explosions: DUO, KTTA, TBIO, GOTUWatch Peraso Inc. (NASDAQ: PRSO) Now Amid Breakout Momentum! - openPR

Sep 26, 2024
pulisher
Sep 26, 2024

Schwab Splitting Shares for Two-Thirds of ETF Lineup - Yahoo! Voices

Sep 26, 2024
pulisher
Sep 26, 2024

Biotech Stock Pasithea Therapeutics Corp. (NASDAQ: KTTA) Soars on Positive Data from Phase 1 Clinical Trials - Investorideas.com newswire

Sep 26, 2024
pulisher
Sep 26, 2024

Dow Surges Over 250 Points; Accenture Earnings Top Views - Benzinga

Sep 26, 2024
pulisher
Sep 26, 2024

Stocks Stay Higher With Tech Still Driving Gains: Markets Wrap - Yahoo Finance

Sep 26, 2024
pulisher
Sep 26, 2024

Why XPeng Stock Spiked Higher Today - Yahoo! Voices

Sep 26, 2024
pulisher
Sep 26, 2024

Why Is Pasithea Therapeutics Stock Surging On Thursday? - AOL

Sep 26, 2024
pulisher
Sep 26, 2024

KTTA’s price-to-free cash flow ratio: What it means for investors - US Post News

Sep 26, 2024
pulisher
Sep 26, 2024

Crude Oil Down Over 2%; US Initial Jobless Claims Fall - Benzinga

Sep 26, 2024
pulisher
Sep 26, 2024

English cricket ‘disconnected from reality’ in valuation of the Hundred - Yahoo! Voices

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics Shares Move Higher After Positive Data for Cancer Treatment - MarketWatch

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea reports positive early data on cancer drug PAS-004 - Investing.com India

Sep 26, 2024
pulisher
Sep 26, 2024

Visa agrees to buy AI-focused enterprise tech firm Featurespace - Yahoo! Voices

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics (KTTA) Sees Strong Pre-Market Gains - Stocks Telegraph

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics rises on positive early-stage data from cancer drug - XM

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics : Investor Presentation - Marketscreener.com

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), And Preliminary Efficacy Data From Its Phase 1 Clinical T... - MENAFN.COM

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics announces initial data from Phase 1 trial of PAS-004 - TipRanks

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics (KTTA) Reports Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from Phase 1 Trial of PAS-004 - StreetInsider.com

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics Announces Positive Initial Safety, - GlobeNewswire

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - StockTitan

Sep 26, 2024
pulisher
Sep 25, 2024

Factbox-OpenAI key personnel changes - Yahoo! Voices

Sep 25, 2024
pulisher
Sep 25, 2024

Why Viking Therapeutics Stock Was So Healthy on Wednesday - Yahoo Finance

Sep 25, 2024
pulisher
Sep 25, 2024

Pasithea Therapeutics Corp. announced that it expects to receive $5.000003 million in funding - Marketscreener.com

Sep 25, 2024
pulisher
Sep 25, 2024

Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note - Yahoo Finance

Sep 25, 2024
pulisher
Sep 25, 2024

Capstan Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance

Sep 25, 2024
pulisher
Sep 23, 2024

BDTX-1535 Generates Early Signals of Antitumor Activity in R/R EGFR+ NSCLC - OncLive

Sep 23, 2024
pulisher
Sep 21, 2024

The OncFive: Top Oncology Articles for the Week of 9/15 - OncLive

Sep 21, 2024
pulisher
Sep 20, 2024

Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel - Yahoo Finance

Sep 20, 2024
pulisher
Sep 19, 2024

CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance

Sep 19, 2024
pulisher
Sep 19, 2024

4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate - Yahoo Finance

Sep 19, 2024
pulisher
Sep 19, 2024

Are Robust Financials Driving The Recent Rally In TG Therapeutics, Inc.'s (NASDAQ:TGTX) Stock? - Yahoo Finance

Sep 19, 2024
pulisher
Sep 19, 2024

Pasithea Therapeutics (NASDAQ:KTTA) Trading Up 25.8% - Defense World

Sep 19, 2024
pulisher
Sep 18, 2024

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know - Yahoo Finance

Sep 18, 2024
pulisher
Sep 17, 2024

KTTAPasithea Therapeutics Corp. Latest Stock News & Market Updates - StockTitan

Sep 17, 2024
pulisher
Sep 17, 2024

Saghmos Therapeutics Announces Presentation at UBS 2024 Biotechnology Private Company Virtual Symposium - Yahoo Finance

Sep 17, 2024

Pasithea Therapeutics Corp Stock (KTTA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):